Literature DB >> 11389509

Staphylococcus epidermidis with intermediate resistance to vancomycin: elusive phenotype or laboratory artifact?

W M Dunne 1, H Qureshi, H Pervez, D A Nafziger.   

Abstract

The recent and troubling isolation of Staphylococcus aureus and coagulase-negative staphylococci that have increased resistance to glycopeptide antibiotics has prompted the use of aggressive surveillance measures in the clinical microbiology laboratory to aid in the recognition of these strains. Despite increasing awareness, the confirmation of glycopeptide resistance among staphylococci can be problematic; we present a case of catheter-associated peritonitis caused by Staphylococcus epidermidis to illustrate the dilemma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389509     DOI: 10.1086/320890

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

1.  Stability of repetitive-sequence PCR patterns with respect to culture age and subculture frequency.

Authors:  Hyunseok Peter Kang; W Michael Dunne
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

Review 2.  Mechanisms of gram-positive vancomycin resistance (Review).

Authors:  Samy Selim
Journal:  Biomed Rep       Date:  2021-11-26

3.  Linezolid Treatment for Osteomyelitis due to Staphylococcus Epidermidis with Reduced Vancomycin Susceptibility.

Authors:  Joon Rok Nam; Myoung Soo Kim; Chae Heuck Lee; Dong Hee Whang
Journal:  J Korean Neurosurg Soc       Date:  2008-06-20

Review 4.  Vancomycin resistance in staphylococci.

Authors:  Arjun Srinivasan; James D Dick; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

5.  Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneri.

Authors:  Kimberly J Center; Annette C Reboli; Robin Hubler; Gail L Rodgers; Sarah S Long
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.